WO2014083432A3 - Female intranasal testosterone gel for treating anorgasmia - Google Patents

Female intranasal testosterone gel for treating anorgasmia Download PDF

Info

Publication number
WO2014083432A3
WO2014083432A3 PCT/IB2013/003121 IB2013003121W WO2014083432A3 WO 2014083432 A3 WO2014083432 A3 WO 2014083432A3 IB 2013003121 W IB2013003121 W IB 2013003121W WO 2014083432 A3 WO2014083432 A3 WO 2014083432A3
Authority
WO
WIPO (PCT)
Prior art keywords
testosterone gel
female
intranasal testosterone
anorgasmia
treating
Prior art date
Application number
PCT/IB2013/003121
Other languages
French (fr)
Other versions
WO2014083432A2 (en
Inventor
Wayne KREPPNER
Siobhan Fogarty
Werner Oberegger
Paul Jose Pierre Marie Maes
Original Assignee
Trimel Biopharma Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trimel Biopharma Srl filed Critical Trimel Biopharma Srl
Publication of WO2014083432A2 publication Critical patent/WO2014083432A2/en
Publication of WO2014083432A3 publication Critical patent/WO2014083432A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Abstract

The present invention relates to lower dosage strength pernasal testosterone gel formulations for intranasal administration and treatment methods for using the lower dosage strength pernasal testosterone gel formulations for treating a female subject with anorgasmia and/or hypoactive sexual desire disorder.
PCT/IB2013/003121 2012-11-14 2013-11-14 Female intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder WO2014083432A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261726570P 2012-11-14 2012-11-14
US61/726,570 2012-11-14
US201261727112P 2012-11-15 2012-11-15
US61/727,112 2012-11-15
US201261729324P 2012-11-21 2012-11-21
US61/729,324 2012-11-21

Publications (2)

Publication Number Publication Date
WO2014083432A2 WO2014083432A2 (en) 2014-06-05
WO2014083432A3 true WO2014083432A3 (en) 2014-10-30

Family

ID=50828553

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/003121 WO2014083432A2 (en) 2012-11-14 2013-11-14 Female intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder

Country Status (1)

Country Link
WO (1) WO2014083432A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102015020878B1 (en) * 2015-08-28 2019-08-27 F B M Ind Farmaceutica Ltda nasal testosterone pharmaceutical formulation and carton-shaped kit of unit nasal devices for testosterone monodose application.
WO2019175290A1 (en) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7404965B2 (en) * 2000-08-03 2008-07-29 Antares Pharma Ipl Ag Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US20100311707A1 (en) * 2003-11-11 2010-12-09 Claudia Mattern Controlled release delivery system for nasal applications and methods of treatment
US8067399B2 (en) * 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
WO2012022446A1 (en) * 2010-08-16 2012-02-23 Innotesto Bvba Testosterone solutions for the treatment of testosterone deficiency

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7404965B2 (en) * 2000-08-03 2008-07-29 Antares Pharma Ipl Ag Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US20100311707A1 (en) * 2003-11-11 2010-12-09 Claudia Mattern Controlled release delivery system for nasal applications and methods of treatment
US8067399B2 (en) * 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
WO2012022446A1 (en) * 2010-08-16 2012-02-23 Innotesto Bvba Testosterone solutions for the treatment of testosterone deficiency

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MILLER, HB ET AL.: "Female Sexual Dysfunction: Review of the Disorder and Evidence for Available Treatment Alternatives.", JOUMAL OF PHARMACY PRACTICE., vol. 16, no. 3, pages 200 - 208 *

Also Published As

Publication number Publication date
WO2014083432A2 (en) 2014-06-05

Similar Documents

Publication Publication Date Title
HK1223301A1 (en) Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
MX2019004364A (en) Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder.
HK1210968A1 (en) Compositions and treatment for eye diseases and disorders
MX356525B (en) Aav -vectors for use in gene therapy of choroideremia.
JO3343B1 (en) Novel5-aminotetrahydroquinoline-2-carboxylic acids and their use
GB201410847D0 (en) Devices and methods for promoting female sexual wellness
EP2863949A4 (en) Methods of treating or preventing periodontitis and diseases associated with periodontitis
DK3292875T3 (en) Compositions and methods for treating diseases
HK1215173A1 (en) Methods of treating s. aureus-associated diseases
PT2810599T (en) Electrostimulation system for the treatment of sleep apnoea
ZA201500547B (en) Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
PL2892556T3 (en) Compositions and methods relating to the treatment of diseases
MX2020009966A (en) Dosage forms and therapeutic uses l-4-chlorokynurenine.
EP2814474A4 (en) Methods of treating and preventing diseases and disorders of the central nervous system
MX356317B (en) Treatment of symptoms associated with female gastroparesis.
IL233225A0 (en) Methods and formulations for treating sialic acid deficiencies
EP2872166A4 (en) Compositions and methods for detecting, treating and preventing diseases and disorders
ZA201408060B (en) Compositions and methods for the treatment of neurological disorders
WO2014083432A3 (en) Female intranasal testosterone gel for treating anorgasmia
ZA201408061B (en) Compositions and methods for the treatment of neurological disorders
WO2012136351A8 (en) Tapentadol for treating pain associated with trigeminal neuralgia
MX2015001695A (en) Treatment regimens.
ZA201309052B (en) Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
HUP1300025A2 (en) Composition for improving the efficiency of uvb light therapy, process for their preparation and use thereof
MX2013006633A (en) Beta-hydroxy-gamma-aminophosphonates for treating immune disorders.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13857940

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13857940

Country of ref document: EP

Kind code of ref document: A2